Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P59 in outpatients with SARS-CoV-2 infection
KCT0005641Phase 3Completed
- Sponsor
- Celltrion
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of regdanvimab in coronavirus disease 2019 (COVID-19), sponsored by Celltrion. Started Oct 2020; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0005641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005641.